ABSTRACT
Conclusions: When distinguishable from M-protein, t-mAbs are detectable in 93% of treated patients as soon as 7 days after the initial dose and are consistently observed throughout induction therapy, warranting increased monitoring and careful interpretation of SPE/IF.
Two novel therapeutic monoclonal antibody (t-mAb) therapies recently have been approved by the US Food and Drug Administration for the treatment of relapsed/ refractory multiple myeloma (MM): daratumumab, a human immunoglobulin G1 (IgG1) κ that binds CD38, and elotuzumab, a humanized IgG1 κ that targets signaling lymphocytic activation molecule F7 (SLAMF7). 1, 2 These antibodies have immune modulatory effects and are postulated to act in part by increasing antibody-dependent cell-mediated cytotoxicity against malignant plasma cells. Daratumumab was initially approved as a single agent to treat patients with MM who have failed at least one conventional treatment and is now approved for combination therapy in refractory patients based on two large randomized trials. 3, 4 Elotuzumab, in combination with dexamethasone/lenalidomide, has been shown to increase progression-free survival in patients with refractory disease 5 ; current studies are under way to evaluate the efficacy of these new therapies as first-line treatment. In addition to these proven therapies, other promising antibody-based modalities are currently being tested in the later phases of the drug discovery pipeline. [6] [7] [8] [9] Because monitoring of disease progression in patients with MM includes routine serum protein electrophoresis (SPE) and immunofixation (IF) for detection of disease-related monoclonal (M) protein, [10] [11] [12] false-positive or misleading results caused by administered t-mAb are a legitimate concern. The potential for false-positive SPE/ IF results from other t-mAbs, such as rituximab, bevacizumab, and ofatumumab, has been reported using spiking studies as well as by examining serum samples from treated patients. [13] [14] [15] Our clinical laboratory has noted the rare detection of rituximab by SPE/IF in treated patients with lymphoplasmacytic lymphoma (unpublished data). False-positive results induced by t-mAbs in patients with MM in particular are especially problematic, as current guidelines designate complete remission (CR) criteria as including no detectable M protein by SPE or IF. [10] [11] [12] Moreover, achievement of CR is emerging as a significant therapeutic milestone in different stages of disease; therefore, robust and reliable measurements to characterize CR in MM are critical. [16] [17] [18] With current recommended dosing schedules, the mean serum peak concentration is approximately 0.09 g/dL for daratumumab and approximately 0.03 g/dL for elotuzumab, close to the limits of detection for M proteins by SPE and IF (0.1 g/dL and 0.02 g/dL, respectively). 19 In addition, these limits of detection may be lower in patients with MM having hypogammaglobulinemia associated with disease and/or therapy, further increasing the potential for these t-mAbs to confound follow-up SPE/ IF results. When added to serum of healthy volunteers at clinically relevant concentrations, both of these t-mAbs are reportedly detectable by standard SPE/IF with characteristic migration patterns: daratumumab has a cathodal migration, while elotuzumab is more anodal in the γ-globulin region. 19, 20 If a patient's disease-associated M protein has the same isotype and migration pattern as the t-mAb, it is impossible to distinguish the two by SPE or IF, and determination of CR theoretically may not be possible by SPE/IF. If the disease M protein has the same migration pattern but a different isotype from the t-mAb, care must be used to follow the patient by IF and not SPE alone. In addition to confounding determination of CR, the detection of exogenous monoclonal antibodies by SPE/IF in treated patients with MM could potentially cause inaccurate reporting or misinterpretation of test results.
Although individual cases of detecting daratumumab or elotuzumab in treated patients with MM have been reported, [20] [21] [22] to our knowledge, the interference of t-mAbs with routine SPE/IF has not been systematically studied in a larger series of patients throughout the duration of therapy. Thus, we sought to examine the frequency of t-mAb detection in routine SPE/IF testing by performing retrospective review of follow-up SPE/IF gels in 22 patients, with a total of 26 courses of therapy (12 elotuzumab and 14 daratumumab). In addition, we examined the timing of detecting t-mAbs to characterize first appearance and persistence during and after therapy. We show that t-mAbs are detectable in nearly all treated patients, with reproducible persistence throughout therapy in most patients. Therefore, clinical pathologists and clinicians must exercise increased vigilance when interpreting SPE/IF results from patients with MM receiving these therapies.
Materials and Methods

Patient Selection
Through pharmacy chart review over a 19-month period, we identified 26 courses of daratumumab or elotuzumab therapy in patients having at least one subsequent SPE/IF available for review. All patients were treated at University Hospitals of Cleveland Medical Center (UHCMC) Seidman Cancer Center with standard dosing of 10 mg/kg for elotuzumab and 16 mg/kg for daratumumab. Twenty-two patients were identified, who in total underwent 12 courses of elotuzumab and 14 courses of daratumumab (some patients received separate courses of both drugs). This study, including retrospective chart review, was approved by the UHCMC Institutional Review Board.
SPE/IF Instrumentation and Determination of t-mAb Migration
SPE analysis was performed using the Sebia Capillarys system (Sebia USA, Norcross, GA), and IF was performed using the Sebia Hydrasys (Sebia USA). Monoclonal peaks were quantified using Sebia Phoresis software (Sebia USA). To establish the characteristic migration pattern of t-mAbs, discarded vials of daratumumab (Janssen Biotech, Horsham, PA) and elotuzumab (Bristol Meyers Squibb, Princeton, NJ) were obtained from the Seidman Cancer Center Pharmacy. Each t-mAb was diluted in pooled normal serum samples at multiple concentrations and analyzed by SPE and IF.
Review of Clinical SPE/IF Results
For all patients with MM, diagnostic or disease-positive SPE tracings and IF gels were reviewed to confirm the position of the myeloma M protein and whether it would be distinguishable from a t-mAb band. In patients with M protein distinguishable from t-mAb, diagnostic SPE/IF results were then compared with SPE/IF performed immediately prior to initiation of therapy, as well as to all subsequent routine follow-up SPE/IF testing, up to 12 weeks after the last administered dose. The presence of a distinct band with migration and isotype consistent with t-mAb was noted for each SPE and/or IF analysis performed after therapy initiation.
Results
Characteristic Migration and Limit of Detection of t-mAbs by SPE/IF
Consistent with previously reported results, 20, 21 in pooled normal serum samples spiked with drug, elotuzumab migrated at a more anodal position and daratumumab migrated at a cathodal position in the γ-globulin region ❚Figure 1A❚. On Sebia Capyllaris2 SPE tracings, both antibodies were readily visible at concentrations of 0.05 and 0.1 g/dL, with very minor peaks at 0.025 g/dL. By IF, t-mAbs were readily discerned as monoclonal IgG κ at all concentrations ❚Figure 1B❚. Thus, the limit of detection for t-mAbs in a normal γ-globulin background was less than 0.05 g/dL by SPE and less than 0.025 g/dL by IF.
Patient Population
All 22 study patients had relapsed or refractory myeloma and together received a total of 26 individual courses of t-mAb therapy ❚Table 1❚, with patients receiving standard dosing of 10 mg/kg elotuzumab and 16 mg/kg daratumumab. Over the 19-month study period, the number of infusions per patient ranged from two to 41, with eight patients still continuing with therapy at the end of the study period. The first follow-up SPE or IF ranged from 7 to 49 days after treatment start. Subsequent follow-up testing also varied widely, without a predictable pattern.
t-mAbs May Not Be Distinguishable From M-Protein Due to Identical Migration or Lack of IF
In two elotuzumab and three daratumumab cases, the t-mAb shared the same migration and isotype with the patient's myeloma M protein (Table 1) . In all five of these cases, M protein levels remained at least 0.9 g/dL throughout therapy, and both the position and the prominence of the M spike obscured viewing of a t-mAb band. In eight additional occurrences of therapy, t-mAb shared the same SPE migration but a different isotype from the myeloma M protein, such that only IF testing could differentiate the two different bands (Table 1) . However, follow-up IF results were not available for five of these therapy occurrences, so these cases could not be studied further. Thus, in a total of 10 of 26 occurrences of therapy, the presence of t-mAb could not be definitively assessed either due to the t-mAb having the same migration and isotype as the significant persistent myeloma M protein or the lack of follow-up IF testing. ❚Figure 2❚ illustrates a case where IF was necessary to distinguish elotuzumab from endogenous myeloma IgA κ-both shared the same migration on SPE (Figure 2A ) and were distinguishable only by IF after start of therapy ( Figure 2B ). Six months after therapy initiation, SPE continued to show a peak in the original M protein position, while IF indicated only the presence of IgG κ (elotuzumab; (Figure 2C ), indicating CR that was discernible only by IF.
Pattern and Duration of t-mAb Appearance in Samples With Distinguishable M Protein
In 16 courses of therapy, t-mAb could be distinguished from the myeloma M protein due to distinct migration or isotype, with informative follow-up testing ❚Table 2❚. In these patients, elotuzumab was detectable in six of seven courses by SPE and/or IF, while daratumumab was detected in nine of nine courses, with both drugs present at concentrations at or below 0.1 g/dL. t-mAb was never observed at a quantity over 0.1 g/dL, consistent with known peak serum drug concentrations. Earliest detection of t-mAb varied widely between patients and was largely dependent on the timing of first SPE/IF follow-up ( Table 2 ). The earliest t-mAb detection was 7 days after start of therapy (MM1), with latest detection at 101 days (MM2). t-mAb was detected on the first follow-up SPE/IF in 80% of patients having detectable t-mAb ( Table 2) .
Duration of t-mAb Detection by Follow-up SPE/IF
In all patients with elotuzumab detected by SPE/ IF, the elotuzumab band persisted throughout the duration of therapy and was even detectable 70 days after treatment cessation in patient MM7 ❚Figure 3A❚ and ❚Figure 3B❚. Daratumumab was also consistently detected throughout induction therapy (weekly infusions) but was variably present in patients receiving biweekly or monthly (maintenance) infusions ❚Figure 3C❚ and ❚Figure 3D❚. Interestingly, daratumumab disappeared from follow-up SPE/IF in four of six patients receiving maintenance daratumumab ( Figure 3D ) ❚Figure 3E❚. In two patients whose daratumumab course ended during the study period, t-mAb was detected by SPE/IF up to 11 days after treatment cessation.
Discussion
The incidence, timing, and long-term persistence of t-mAb observed with routine follow-up SPE/IF testing have not been previously reported in a series of treated patients with MM. Our results demonstrate that daratumumab and elotuzumab are detected by routine SPE/IF in over 90% of treated patients in whom the t-mAb is distinguishable from the myeloma M protein. Interestingly, t-mAb could be distinguished from myeloma M protein by either distinct SPE migration or different isotype (ascertained by IF) in most treatment occurrences (21/26), although follow-up IF was not ordered in every case. This observation demonstrates the necessity for ordering routine follow-up IF in patients whose M protein shares the same SPE migration, but not isotype, of t-mAb.
The detection of a t-mAb band by SPE/IF may cause confusion in interpretation of results in several ways: (1) the t-mAb may be misinterpreted as the disease M protein by the clinical laboratory, with reporting of a false-positive result, as often the laboratory does not receive treatment history of patients, and (2) CR may not be determinable if the t-mAb cannot be distinguished from the disease M protein. When detected by routine SPE/IF, the concentration of elotuzumab or daratumumab was never noted to be higher than 0.1 g/dL, so the presence of t-mAb is of concern mainly when excluding residual disease or a new monoclonal gammopathy.
In our series, detection of elotuzumab was consistent throughout the duration of therapy in all treated patients, and elotuzumab was detectable as long as 70 days after therapy cessation. In contrast, detection of daratumumab persisted throughout weekly infusion in all patients but was more variable during biweekly or monthly (maintenance) infusions. The exact range of weeks for persistence of t-mAb after therapy cessation is difficult to determine from our cohort since frequency of follow-up testing varied widely between patients, and many patients were still undergoing maintenance therapy at the end of the study period. Clearance of antibody should vary between patients based on weight and renal function, and further longitudinal studies with a larger group of patients are needed to determine the range of t-mAb persistence after the last dose. An assay to mitigate the confounding effects of daratumumab on SPE/IF results has been developed, the daratumumab IF reflex assay, which observes changes in the migration of daratumumab after binding to an anti-idiotype antibody. 21, 23 The assay demonstrates 100% reproducibility as well as high specificity, and while this assay is capable of distinguishing daratumumab interference, it is applicable only to daratumumab. The strategy of using anti-idiotype antibodies to abrogate t-mAb interference requires a different anti-idiotype antibody for each t-mAb. With numerous t-mAbs under development for MM, 19 development of multiple anti-idiotype antibodies is a considerable task, and the use of multiple types of these assays may prove to be cost-and labor-intensive for many clinical laboratories. Recently, mass spectrometry has been used to detect monoclonal proteins in serum, 24, 25 and this technique may prove useful for distinguishing t-mAbs from disease M proteins. 19 However, the use of mass spectrometry in the clinical chemistry laboratory is not routine and therefore may not be feasible for many laboratories.
Until practical laboratory assays are developed for mitigating the interference of t-mAbs with SPE/IF, the serum free light chain assay may be useful for monitoring residual disease, although this assay does not directly measure the myeloma M protein. Because this assay measures unbound light chains in serum, it should not be affected by administered t-mAb (Sebia, unpublished communication). One published report has indicated no interference by daratumumab with serum free light chain assay results when comparing M protein-positive serum samples before and after addition of daratumumab. 26 Further studies with clinical correlates are necessary to demonstrate whether the serum free light chain assay would be adequate by itself for monitoring residual disease in patients treated with t-mAb.
In conclusion, because of the increasing use of elotuzumab and daratumumab in MM therapy, with more t-mAbs currently being developed, both clinical pathologists and oncologists should be aware of the high frequency of detection and long-term persistence of t-mAb in routine follow-up SPE/IF. Careful interpretation of SPE/IF results is necessary in patients with MM undergoing these therapies.
